Oncimmune announces the signature of Agreements with Roche and Cedars-Sinai to profile patients using Oncimmune's novel Infectious Disease panel
![Oncimmune 300x300](https://ipfpartners.com/wp-content/uploads/2019/10/Oncimmune-300x300.jpg)
Oncimmune Holdings plc, the leading global immunodiagnostics group, today announces that it has signed two separate agreements with Roche Pharmaceuticals (“Roche”) and Cedars-Sinai Medical Center (“Cedars-Sinai”), in each case to use the Company’s newly developed and proprietary Infectious Disease panel.